Key result
Adding low-dose rivaroxaban to DAPT achieves ~25-point greater thrombus score reduction in STEMI.
Why the study?
Managing large coronary thrombus burden in STEMI remains challenging, and the optimal antithrombotic regimen for patients managed with deferred stenting is unclear.
Does adding low-dose rivaroxaban to dual antiplatelet therapy reduce thrombus burden in STEMI patients with large coronary thrombus burden managed with deferred stenting?
RCT (n=40)
Open-label
1:1
No
Does adding low-dose rivaroxaban to dual antiplatelet therapy reduce thrombus burden in STEMI patients with large coronary thrombus burden managed with deferred stenting?
Absolute Event Rate: 61% vs 36%
p-value: p=0.002
Early addition of short-term, low-dose rivaroxaban to standard dual antiplatelet therapy safely and significantly enhances thrombus reduction in STEMI patients with large coronary thrombus burden undergoing deferred stenting.
Supports adjunctive low-dose rivaroxaban for greater thrombus reduction in high-burden STEMI deferred stenting; extends antithrombotic options beyond DAPT alone.
Background Managing large coronary thrombus burden (LCTB) in patients with ST‐segment–elevation myocardial infarction (STEMI) remains challenging. Although deferred stenting emerged to potentially improve outcomes in this high‐risk population, the optimal antithrombotic regimen remains unclear. The ARISE‐ARMYDA 7 (Alternative Anti‐Thrombotic Pathways in Acute Myocardial Infarction–Antiplatelet Therapy for Reduction of Myocardial Damage 7) trial evaluated low‐dose rivaroxaban in addition to dual antiplatelet therapy for LCTB reduction in patients with STEMI managed with deferred stenting. Methods This single‐center, randomized, pilot study included patients with STEMI with angiographic evidence of LCTB undergoing primary percutaneous coronary intervention and deferred stenting. Patients were randomized to rivaroxaban 2.5 mg BID plus aspirin and ticagrelor or aspirin plus ticagrelor alone. Thrombus burden was assessed by optical coherence tomography at baseline and after 5 to 7 days of treatment. The primary end point was reduction of thrombus score after this period. Results A total of 40 patients with STEMI and LCTB were randomized 1:1. Posttreatment thrombus score at re‐optical coherence tomography imaging was significantly lower in the rivaroxaban arm (39 [27–52] versus 82 [50–111] in controls, P =0.005). Relative reduction of the thrombus score versus baseline was greater with rivaroxaban use (61% [50%–81%] versus 36% [0%–50%], P =0.002). The relative thrombus volume decrease was 77% with rivaroxaban versus 39% in the control arm ( P =0.001). Deferred stenting was safe, with no abrupt vessel closures, distal embolization, or no reflow. Clinical outcomes at 30 days, including major adverse cardiovascular events and bleeding complications, were not significantly different. Conclusions The ARISE‐ARMYDA 7 trial shows that adding low‐dose rivaroxaban to dual antiplatelet therapy significantly reduces thrombus burden in patients with STEMI with LCTB, while maintaining a favorable safety profile. Registration URL: https://www.clinicaltrialsregister.eu/ ; Unique identifier: EudraCT 2020–005156‐38.
No takes yet. Share an insight, caveat, or question.
Mennuni et al. (2025) conducted an RCT in ST-segment-elevation myocardial infarction (STEMI) with large coronary thrombus burden (n=40). Rivaroxaban vs. Dual antiplatelet therapy (aspirin plus ticagrelor) alone was evaluated on Relative reduction of OCT-derived thrombus score from baseline at 5-7 days (p=0.002). Adding low-dose rivaroxaban to dual antiplatelet therapy significantly increased the median relative reduction of thrombus score (61% vs 36%, P=0.002) in STEMI patients with large thrombus burden.